Bee venom 5,000 SQ-U/5ml suspension for injection vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Alutard brand family (generic: Bee venom)
MHRA licensed products
View all licensed products for Bee venom on the MHRA register
Alutard SQ Bee Venom 5,000 SQ-U/5ml suspension for injection vials
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Anaphylaxis (QS119)
Omalizumab for treating severe persistent allergic asthma (TA278)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 26 · Randomised trials: 2 · 1972–2025
Showing the 50 most relevant studies, sorted by most relevant.
LUCAS FORNARI LAURINDO, Enzo Pereira de Lima, Lívia Fornari Laurindo, et al.
Pharmacological research, 2024
- Neoplasms
- Bee Venoms
- Apamin
Rim Wehbe, Jacinthe Frangieh, Mohamad Rima, et al.
Molecules, 2019
- Bee Venoms
- Bees
- Central Nervous System Diseases
Islam Rady, Imtiaz A. Siddiqui, Mohamad Rady, et al.
Cancer Letters, 2017
- Antineoplastic Agents
- Drug Carriers
- Drug Compounding
Gihyun Lee, Hyunsu Bae
Molecules, 2016
- Anti-Inflammatory Agents
- Bee Venoms
- Melitten
Manuela B. Pucca, Felipe A. Cerni, Isadora Sousa de Oliveira, et al.
Frontiers in Immunology, 2019
- Bee Venoms
- Bees
- Americas
Shuai Zhang, Yi Liu, Ye Yang, et al.
Toxicon, 2018
- Bees
- Bee Venoms
- Insect Bites and Stings
J. Park, Bokyung Yim, Jun-Hwan Lee, et al.
PLoS ONE, 2015
- Anaphylaxis
- Bee Venoms
- Drug Hypersensitivity
María Carpena, Bernabé Núñez-Estévez, Anton Soria-López, et al.
Nutrients, 2020
- Bee Venoms
- Bees
- Biological Products
Jeong H, Kim KH, Ko SG
2025
- Parkinson Disease
- Bee Venoms
- Acupuncture Therapy
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, affecting over 8.5 million people as of 2019. While standard pharmacological treatments help alleviate symptoms, their long-term use can lead to side effects such as dyskinesia. Bee venom acupuncture (BVA) involves the use of a natural toxin derived from bees that can be used for pain relief and treating neurological disorders. This study aimed to review the efficacy and safety of BVA for the treatment of PD. This review protocol was prospectively registered with PROSPERO (CRD420251000577). We searched eight databases in February 2025 and selected 12 studies involving 215 PD patients treated with BVA. Idiopathic Parkinson's disease (IPD) is the most common diagnosis. The concentration and dosage per session ranged from 0.03 to 0.1 mg/mL and from 0.1 to 1.0 mL, respectively. Twenty-four different outcome measures were used, with the Unified PD Rating Scale employed in 91.7% of the studies. All studies reported improvements in outcomes. Mild adverse effects such as swelling and itching were noted in four studies (33.3%); however, no severe reactions such as anaphylactic shock occurred. These findings suggest that BVA has the potential for broader clinical applications in the treatment of PD.
Abstract licence: CC BY
Ju Ah Lee, Mi Ju Son, Jiae Choi, et al.
BMJ Open, 2014
- Acupuncture Therapy
- Arthritis, Rheumatoid
- Bee Venoms
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.